+

WO2002026998A3 - Hydrolases - Google Patents

Hydrolases Download PDF

Info

Publication number
WO2002026998A3
WO2002026998A3 PCT/US2001/030310 US0130310W WO0226998A3 WO 2002026998 A3 WO2002026998 A3 WO 2002026998A3 US 0130310 W US0130310 W US 0130310W WO 0226998 A3 WO0226998 A3 WO 0226998A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydr
hydrolases
provides
polynucleotides
agonists
Prior art date
Application number
PCT/US2001/030310
Other languages
French (fr)
Other versions
WO2002026998A2 (en
Inventor
Henry Yue
Mariah R Baughn
Bridget A Warren
Catherine M Tribouley
Y Tom Tang
Farrah A Khan
Monique G Yao
Preeti Lal
Michael Thornton
Original Assignee
Incyte Genomics Inc
Henry Yue
Mariah R Baughn
Bridget A Warren
Catherine M Tribouley
Y Tom Tang
Farrah A Khan
Monique G Yao
Preeti Lal
Michael Thornton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Henry Yue, Mariah R Baughn, Bridget A Warren, Catherine M Tribouley, Y Tom Tang, Farrah A Khan, Monique G Yao, Preeti Lal, Michael Thornton filed Critical Incyte Genomics Inc
Priority to US10/382,000 priority Critical patent/US20040072190A1/en
Priority to CA002423953A priority patent/CA2423953A1/en
Priority to EP01975504A priority patent/EP1341921A2/en
Priority to AU2001294823A priority patent/AU2001294823A1/en
Priority to JP2002530761A priority patent/JP2004524815A/en
Publication of WO2002026998A2 publication Critical patent/WO2002026998A2/en
Publication of WO2002026998A3 publication Critical patent/WO2002026998A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides human hydrolases (HYDR) and polynucleotides which identify and encode HYDR. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of HYDR.
PCT/US2001/030310 2000-09-29 2001-09-28 Hydrolases WO2002026998A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/382,000 US20040072190A1 (en) 2001-09-28 2001-09-28 Hydrolases
CA002423953A CA2423953A1 (en) 2000-09-29 2001-09-28 Hydrolases
EP01975504A EP1341921A2 (en) 2000-09-29 2001-09-28 Hydrolases
AU2001294823A AU2001294823A1 (en) 2000-09-29 2001-09-28 Hydrolases
JP2002530761A JP2004524815A (en) 2000-09-29 2001-09-28 Hydrolase

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US23709300P 2000-09-29 2000-09-29
US60/237,093 2000-09-29
US23837000P 2000-10-06 2000-10-06
US60/238,370 2000-10-06
US24128400P 2000-10-17 2000-10-17
US60/241,284 2000-10-17

Publications (2)

Publication Number Publication Date
WO2002026998A2 WO2002026998A2 (en) 2002-04-04
WO2002026998A3 true WO2002026998A3 (en) 2003-07-17

Family

ID=27398946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030310 WO2002026998A2 (en) 2000-09-29 2001-09-28 Hydrolases

Country Status (5)

Country Link
EP (1) EP1341921A2 (en)
JP (1) JP2004524815A (en)
AU (1) AU2001294823A1 (en)
CA (1) CA2423953A1 (en)
WO (1) WO2002026998A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156259A1 (en) * 2000-08-15 2002-10-24 Conklin Darrell C. Human adenosine deaminase
AU2001285102A1 (en) 2000-08-21 2002-03-04 Bristol-Myers Squibb Company Adenosine deaminase homolog
WO2002074960A2 (en) * 2000-11-08 2002-09-26 Millennium Pharmaceuticals, Inc. 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
DK2853593T3 (en) 2003-03-07 2018-01-08 Dsm Ip Assets Bv Hydrolases, nucleic acids encoding them, and processes for their preparation and use
US20080070291A1 (en) 2004-06-16 2008-03-20 David Lam Compositions and Methods for Enzymatic Decolorization of Chlorophyll

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028045A2 (en) * 1998-11-12 2000-05-18 Incyte Pharmaceuticals, Inc. Human hydrolase proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028045A2 (en) * 1998-11-12 2000-05-18 Incyte Pharmaceuticals, Inc. Human hydrolase proteins

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHANG Z ET AL: "DEDUCED AMINO ACID SEQUENCE OF ESCHERICHIA-COLI ADENOSINE DEAMINASE REVEALS EVOLUTIONARILY CONSERVED AMINO ACID RESIDUES IMPLICATIONS FOR CATALYTIC FUNCTIONS", BIOCHEMISTRY, vol. 30, no. 8, 1991, pages 2273 - 2280, XP002210562, ISSN: 0006-2960 *
DATABASE EMBL [online] EBI; 3 March 2000 (2000-03-03), NCI-CGAP: "gf44c04.x1 Soares testis NHT Homo sapiens cDNA clone", XP002210564, Database accession no. AI150008 *
DATABASE EMBL [online] EBI; 8 June 2000 (2000-06-08), HEGDE P. ET AL.: "Assessment of gene expression patterns in a model of colon tumor metastasis using a 19200 element cDNA microarray", XP002210565, retrieved from EMBL Database accession no. AW964086 *
HEGDE, P.ET AL.: "Identification of tumor markers in models of human colorectal cancer using a 19200-element complementary DNA microarray", CANCER RESEARCH, vol. 61, no. 21, 1 November 2001 (2001-11-01), pages 7792 - 7797, XP002210615 *
HERSHFIELD M S ET AL: "Clinical expression, genetics and therapy of adenosine deaminase (ADA) deficiency.", JOURNAL OF INHERITED METABOLIC DISEASE, vol. 20, no. 2, 1997, pages 179 - 185, XP001097451, ISSN: 0141-8955 *
MORISAKI T ET AL: "ADENYLATE DEAMINASE A MULTIGENE FAMILY IN HUMANS AND RATS", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 20, 1990, pages 11482 - 11486, XP002210563, ISSN: 0021-9258 *
VALENZUELA A ET AL: "HIV-1 envelope gp120 and viral particles block adenosine deaminase binding to human CD26.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. UNITED STATES 1997, vol. 421, 1997, pages 185 - 192, XP001097454, ISSN: 0065-2598 *

Also Published As

Publication number Publication date
WO2002026998A2 (en) 2002-04-04
JP2004524815A (en) 2004-08-19
CA2423953A1 (en) 2002-04-04
AU2001294823A1 (en) 2002-04-08
EP1341921A2 (en) 2003-09-10

Similar Documents

Publication Publication Date Title
WO2001098468A3 (en) Proteases
WO2003052075A3 (en) Enzymes
WO2001007628A3 (en) Human synthetases
WO2002008396A3 (en) Human proteases
WO2002018557A3 (en) Human kinases
WO2001096547A3 (en) Human kinases
WO2001060991A3 (en) Human kinases
WO2001098354A3 (en) Human receptors
WO2001051638A3 (en) Drug metabolizing enzymes
WO2001090334A3 (en) Drug metabolizing enzymes
WO2001072777A3 (en) Human transcription factors
WO2001046397A3 (en) Human kinases
WO2002004612A3 (en) Drug metabolizing enzymes
WO2003042357A3 (en) Enzymes
WO2002038744A3 (en) Proteases
WO2002026950A3 (en) Transferases
WO2001071004A3 (en) Proteases
WO2001096546A3 (en) Protein phosphatases
WO2001098471A8 (en) Human phosphodiesterases
WO2001085942A3 (en) Cytoskeleton-associated proteins
WO2002010363A3 (en) Protein phosphatases
WO2000042201A3 (en) Human peptidases
WO2001081555A3 (en) Human kinases
WO2001079468A3 (en) Drug metabolizing enzymes
WO2001059127A3 (en) Drug metabolizing enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002530761

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2423953

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10382000

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001975504

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001975504

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001975504

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载